AVTR vs. JAZZ: Avantor vs. Jazz Pharmaceuticals Stock Comparison
How do Avantor (AVTR) and Jazz Pharmaceuticals (JAZZ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while JAZZ is classified in Pharmaceuticals.
| Profile Item | AVTR | JAZZ |
|---|---|---|
| Name | Avantor, Inc. | Jazz Pharmaceuticals plc |
| Country/Region | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 10.48 billion USD | 15.07 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | May 17, 2019 | June 1, 2007 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | JAZZ |
|---|---|---|
| Total Return (1Y) | 36.41% | 84.44% |
| Total Return (3Y, Annualized) | -5.02% | 27.57% |
| Total Return (5Y, Annualized) | -16.62% | 12.88% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | JAZZ |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 38.74% |
| Beta (5Y) | 0.94 | 0.33 |
| Max Drawdown (5Y) | -82.42% | -42.03% |
| Avg. Volume (3M) | 8.56M | 878.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | JAZZ |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 2.07 |
| Sortino Ratio (1Y) | 1.17 | 4.14 |
Profitability
ROE (TTM)
Both Avantor (AVTR) at 5.91% and Jazz Pharmaceuticals (JAZZ) at 5.05% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Avantor (AVTR) at 5.08% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Jazz Pharmaceuticals (JAZZ) at 30.17% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | JAZZ |
|---|---|---|
| ROE (TTM) | 5.91% | 5.05% |
| ROA (TTM) | 2.83% | 6.92% |
| Net Margin (TTM) | 5.08% | 4.37% |
| Operating Margin (TTM) | 8.19% | 30.17% |
| Gross Margin (TTM) | 31.59% | 91.10% |
Growth
Revenue Growth
Jazz Pharmaceuticals (JAZZ) at 4.88% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Both Avantor (AVTR) at -175.00% and Jazz Pharmaceuticals (JAZZ) at -167.51% post bottom-quartile EPS growth versus peers, pointing to weaker earnings momentum than typical rivals.
Growth Metrics
| Metric | AVTR | JAZZ |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | 4.88% |
| Revenue Growth (3Y CAGR) | -4.46% | 5.26% |
| EPS Growth (YoY) | -175.00% | -167.51% |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Avantor (AVTR) at 1.89 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
Debt / Equity (MRQ)
Avantor (AVTR) at 0.63 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | JAZZ |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 1.82 |
| Debt / Equity (MRQ) | 0.63 | 1.35 |
| Net Debt / EBITDA | 3.40 | 1.39 |
Dividends
Dividend Yield (TTM)
Neither Avantor (AVTR) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Avantor (AVTR) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | JAZZ |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Avantor (AVTR) at 30.94 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Jazz Pharmaceuticals (JAZZ) at 3.19 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Avantor (AVTR) at 1.80 and Jazz Pharmaceuticals (JAZZ) at 3.59 are valued close to their industries’ norm against book — neither stands out from peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | JAZZ |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | 69.46 |
| P/S Ratio (TTM) | 1.58 | 3.19 |
| P/B Ratio (MRQ) | 1.80 | 3.59 |
| Free Cash Flow Yield (TTM) | 4.21% | 11.16% |